Zynerba flunks another major trial, all but ending Fragile X hopes
Zynerba’s CBD drug has failed its fourth trial in as many years.
In a pivotal Phase III trial, their lead compound failed to significantly improve …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
